



Washington State Health Care Authority  
**Prescription Drug Program**

P.O. Box 91132 • Seattle, Washington 98111-9232  
206-521-2027 • FAX 206-521-2001 • TTY 360-923-2701 • [www.rx.wa.gov](http://www.rx.wa.gov)

October 8, 2010

Re: November 1, 2010 Preferred Drug List Changes CANCELLED

Dear Interested Party:

The November 1, 2010 changes to the Washington Preferred Drug List (PDL) (announced on September 29, 2010) are cancelled. The agencies will use the PDL as it existed at the time of the last update on April 1, 2010. The current PDL is attached and may also be viewed at: <http://www.rx.wa.gov/documents/washingtonpdl.pdf>. Outstanding manufacturer supplemental rebate offers will be returned without review.

In addition, because of the Centers for Medicare and Medicaid Services delay in publishing the 2010 unit rebate amounts as a result of recent changes to the federal rebate program, as well as uncertainty resulting from the proposed Medicaid budget reductions affecting the adult pharmacy program, the agencies will not conduct cost analyses of the P&T Committee recommendations for the following meetings:

- October 20, 2010
- December 15, 2010
- February 16, 2011

This will allow the agencies to fully incorporate new federal rebate formulas and any program changes resulting from the 2011 Legislative session into our cost model for determining drugs to be included on the PDL. During this time the agencies will not be requesting manufacturer supplemental rebates, and will not be conducting cost analyses on the P&T Committee recommendations. The agencies anticipate that no changes to the PDL will occur as a result of these meetings unless the P&T Committee recommends changes based on clinical or safety concerns.

The P&T Committee will continue to meet as scheduled to conduct ongoing reviews of updated evidence with regard to the current PDL, as well as to provide federally required drug utilization review activities. This will ensure that the existing PDL continues to be consistent with P&T Committee recommendations on drug safety, efficacy and any effects on special populations.

The agencies will resume requesting manufacturer supplemental rebate offers and conducting cost analyses beginning with the April 20, 2011 P&T meeting and continuing thereafter.

The agencies remain committed to an open and transparent PDL development process. We appreciate your patience as we work through a time of change and budget uncertainty. We will continue to provide updated information as it becomes available.

Sincerely,

Duane Thurman  
Director, Prescription Drug Program  
Washington State Health Care Authority